The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Abstract
Interleukin-6 (IL-6) plays pathologic roles in immune-inflammatory diseases such as rheumatoid arthritis (RA) and Castleman disease. By inhibiting IL-6 receptors (IL-6Rs), tocilizumab (a humanized anti–IL-6R antibody) ameliorates the symptoms of these diseases and normalizes acute-phase proteins, including C-reactive protein (CRP). We found that tocilizumab treatment increased serum levels of IL-6 and soluble IL-6R (sIL-6R). To investigate the pathologic significance of these increases, we analyzed the kinetics of serum IL-6 and sIL-6R and the proportion of sIL-6R saturated with tocilizumab after tocilizumab administration in patients with RA and Castleman disease and then compared the results with the CRP values. Serum IL-6 and sIL-6R markedly increased after tocilizumab administration in both RA and Castleman disease. As long as free tocilizumab was detectable, sIL-6R was saturated with tocilizumab and IL-6 signaling was completely inhibited. We concluded that it is likely that sIL-6R increased because its elimination half-life was prolonged by the formation of tocilizumab/sIL-6R immune complex, and that free serum IL-6 increased because IL-6R–mediated consumption of IL-6 was inhibited by the unavailability of tocilizumab-free IL-6R. We also concluded that the increased level of free IL-6 during tocilizumab treatment closely reflects the actual endogenous IL-6 production and true disease activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Self-citationIto, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Self-citation
Cited by
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
Folkersen, L., Gustafsson, S., Wang, Q., Hansen, D. H., Hedman, Å. K., Schork, A., Page, K., Zhernakova, D. V., Wu, Y., Peters, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00287-2 · Cited by 705
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Interleukin-6 and its receptors: a highly regulated and dynamic system
Wolf, J., Rose-John, S., & Garbers, C. (2014) · Cytokine · doi:10.1016/j.cyto.2014.05.024 · Cited by 618
Gruber, C. N., Patel, R. S., Trachtman, R., Lepow, L., Amanat, F., Krammer, F., Wilson, K. M., Onel, K., Geanon, D., Tuballes, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.034 · Cited by 551
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., Machado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., et al. (2021) · BMJ · doi:10.1136/bmj.n84 · Cited by 388
Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., & Nishimoto, N. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211878 · Cited by 344
Self-citationSong, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194
Gupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151
Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes, M., Anderson, G., Kubera, M., & Berk, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.888417 · Cited by 140
Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22110 · Cited by 140
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745320 · Cited by 121
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell, M. J., Kawaguchi, N., Kondo, R., Sonzogni, A., Licini, L., Valle, C., Bonaffini, P. A., Sironi, S., Alessio, M. G., Previtali, G., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.050 · Cited by 111
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
Pierson, S. K., Stonestrom, A. J., Shilling, D., Ruth, J., Nabel, C. S., Singh, A., Ren, Y., Stone, K., Li, H., van Rhee, F., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25123 · Cited by 90
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration
Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.003 · Cited by 83
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis
Ogata, A., Hirano, T., Hishitani, Y., & Tanaka, T. (2012) · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s7371 · Cited by 61
Role of IL-6 trans-signaling in CCl4 induced liver damage
Gewiese-Rabsch, J., Drucker, C., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.023 · Cited by 36
Trinh, B., Peletier, M., Simonsen, C., Plomgaard, P., Karstoft, K., Pedersen, B. K., van Hall, G., & Ellingsgaard, H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac239 · Cited by 7
IL-6 Activity is Required for Maximal Catecholamine Release During High-Intensity Exercise in Men
Ziegler, A. K., Schauer, T., Myrup, S. F., van Hall, G., Pedersen, B. K., Christensen, J. F., & Ellingsgaard, H. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102395 · Cited by 1
Metadata
- Authors
- Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-11-15
- Volume
- 112
- Issue
- 10
- Pages
- 3959-3964
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2023761225
- Cited by
- 795
- References
- 2
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
